PBM Transparency Moves From Reform Proposal to Pricing Design
Optum Rx’s fee-based PBM model adds market context to DOL’s proposed PBM fee-disclosure rule and the broader push for compensation transparency.
Optum Rx says it is offering a fee-based PBM model with monthly per-member fees not tied to manufacturer list prices or prescription volume. The announcement does not prove lower costs or regulatory sufficiency, but it adds a market-side signal to DOL’s proposed PBM fee-disclosure rule for ERISA-covered self-insured group health plans.
What you need to know
- The change: Optum Rx says it is offering a fee-based pharmacy care model that replaces approaches tied to manufacturer-set drug prices or prescription volume with monthly, clearly defined per-member fees. (PharmiWeb.com)
- Who is affected: Optum Rx PBM customers are the immediate audience for the announced offering. Fiduciaries of ERISA-covered self-insured group health plans and benefits leaders should also watch the issue because DOL’s proposed PBM fee-disclosure rule is aimed at improving transparency into PBM compensation. (Federal Register)
- Why it matters: The DOL proposal focuses on what compensation information fiduciaries should receive. Optum’s announcement focuses on how one PBM says it will structure and disclose certain fees.
- What to do first: If responsible for PBM oversight, compare current PBM contract language and reporting against categories appearing across the policy and market conversation: per-member fees, manufacturer payments, GPO-associated fees, spread pricing, and audit rights.
- Key date or trigger: DOL released the proposed rule on January 29, 2026, and it was published in the Federal Register on January 30, 2026. Optum Rx announced its fee-based model on May 11, 2026. (DOL)
The signal is public. The implications are not.
Members receive deeper analysis and early warnings inside the PolicyEdge AI Intelligence Terminal.